Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:51 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention
NCT01245725 · Medicure · PHASE3 · withdrawn · last registry update 2018-03-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was not initiated, change in clinical development” | – | Registry record, Medicure |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ITGB3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-06-08Results posted on the registry: Seoul National University Bundang Hospital, Tirofiban (NCT03114995)
- 2018-02-14Results posted on the registry: Icahn School of Medicine at Mount Sinai, Intravenous Glycoprotein inhibitor + ASA, Clopidogrel + Antiplatelet Therapy (ASA, Clopidogrel) (NCT01103440)
- 2018-01-19Also stopped (withdrawn): M.D. Anderson Cancer Center, Cilengitide + Bevacizumab (NCT01782976)
- 2017-11-29Phase 3 first posted: Capital Medical University, Tirofiban + Alteplase (NCT03357133)
- 2017-08-02Results posted on the registry: Merck KGaA, Darmstadt, Germany, EMD 525797 (NCT00958477)
- 2017-06-14Results posted on the registry: National Cancer Institute (NCI), cilengitide (NCT00112866)
- 2017-06-14Also stopped (terminated): National Cancer Institute (NCI), cilengitide (NCT00112866)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision